Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.61 |
| ▸ | CNR1 | P21554 | 8/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2772044 | 0.92 | CNR2 (0.53) | CNR2CNR1CA1CA2PTGS2 | |
| SCHEMBL12848858 | 0.89 | CNR2 (0.50) | CNR2CNR1PTGS2PTGS1 | |
| SCHEMBL4934621 | 0.82 | CNR2 (0.80) | CNR2CNR1CA1CA2PTGS2 | |
| SCHEMBL2771943 | 0.81 | CNR2 (0.61) | CNR2CNR1CA1CA2PTGS2 | |
| SCHEMBL1927934 | 0.80 | CNR2 (0.84) | CNR2CNR1CA1CA2PTGS2 | |
| SCHEMBL4938480 | 0.77 | CNR2 (0.62) | CNR2CNR1CA1CA2PTGS2 | |
| SCHEMBL2773785 | 0.76 | CNR2 (0.77) | CNR2CNR1CA1CA2PTGS2 | |
| SCHEMBL2772965 | 0.76 | CNR2 (1.00) | CNR2CNR1CA1CA2PTGS2 | |
| SCHEMBL2772364 | 0.75 | CNR2 (1.00) | CNR2CNR1CA1CA2PTGS2 | |
| SCHEMBL2774825 | 0.75 | CNR2 (0.78) | CNR2CNR1CA1CA2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059970-A1 | 4-PHENYL-1,3-THIAZOLES AND 4-PHENYL-1,3-OXAZOLES DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | IPSEN PHARMA S.A.S. (FR) | 2011-03-10 | — | — | US | claimed |
| US-20110059970-A1 | 4-PHENYL-1,3-THIAZOLES AND 4-PHENYL-1,3-OXAZOLES DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | IPSEN PHARMA S.A.S. (FR) | 2011-03-10 | — | — | US | disclosed |
| US-20110059970-A1 | 4-PHENYL-1,3-THIAZOLES AND 4-PHENYL-1,3-OXAZOLES DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | IPSEN PHARMA S.A.S. (FR) | 2011-03-10 | — | — | US | disclosed |
| EP-2201007-A1 | CANNABINOID RECEPTOR LIGANDS | IPSEN PHARMA S.A.S. (FR) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009071753-A1 | CANNABINOID RECEPTOR LIGANDS | IPSEN PHARMA S.A.S. (FR) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071753-A1 | CANNABINOID RECEPTOR LIGANDS | IPSEN PHARMA S.A.S. (FR) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059970-A1 | 4-PHENYL-1,3-THIAZOLES AND 4-PHENYL-1,3-OXAZOLES DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, NPY1R | CNR2 2/4885CNR1 1/4885CA1 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.